Table 1.
Cohort characteristics for derivation and validation samplesa
| Characteristic | Derivation (n = 473) | Validation (n = 380) |
|---|---|---|
| Remission CDAI (CDAI < 2.8 at wk 24) | ||
| No | 395 (83.5%) | 331 (87.1%) |
| Yes | 78 (16.5%) | 49 (12.9%) |
| Age, y | 52.0 (44.0, 60.0) | 53.0 (43.5, 61.5) |
| BMI, kg/m2 | 26.5 (23.2, 30.3) | 26.6 (23.9, 31.0) |
| BMI category | ||
| Normal | 182 (38.5%) | 134 (35.3%) |
| Overweight | 161 (34.0%) | 134 (35.3%) |
| Obesity | 130 (27.5%) | 112 (29.5%) |
| Sex | ||
| Female | 364 (77.0%) | 316 (83.2%) |
| Male | 109 (23.0%) | 64 (16.8%) |
| Race | ||
| Nonwhite | 81 (17.1%) | 92 (24.2%) |
| White | 392 (82.9%) | 288 (75.8%) |
| Region | ||
| Asia, Australia, New Zealand, Africa, Turkey | 42 (8.9%) | 46 (12.1%) |
| Europe | 274 (57.9%) | 138 (36.3%) |
| North America | 91 (19.2%) | 114 (30.0%) |
| South America | 66 (14.0%) | 82 (21.6%) |
| HAQ‐DI | 1.6 (1.0, 2.0) | 1.6 (1.1, 2.0) |
| Disease duration, y | 0.9 (0.2, 4.8) | 3.6 (1.0, 9.6) |
| Baseline CDAI | 39.1 (30.1, 48.6) | 41.3 (32.8, 50.5) |
| Patient's global assessment of disease activity | 69.0 (52.0, 81.0) | 68.0 (50.0, 81.0) |
| Physician's global assessment of disease activity | 64.0 (51.0, 76.0) | 64.0 (52.0, 76.0) |
| Swollen joint count (28 joints) | 10.0 (7.0, 15.0) | 12.0 (8.0, 16.0) |
| Tender joint count (28 joints) | 15.0 (10.0, 21.0) | 17.0 (11.0, 23.0) |
| ESR result, mm/h | 40.0 (29.0, 60.0) | 42.0 (30.0, 61.5) |
| High‐sensitivity CRP, mg/l | 10.2 (4.0, 24.5) | 15.7 (6.9, 38.5) |
| Hematocrit, % | 0.39 (0.36, 0.41) | 0.39 (0.36, 0.42) |
| Hemoglobin, mg/dl | 12.6 (11.7, 13.8) | 12.6 (11.5, 13.5) |
| Past DMARD and/or methotrexate use | ||
| Both no | 193 (40.8%) | 98 (25.8%) |
| Both yes | 221 (46.7%) | 220 (57.9%) |
| DMARD, yes; methotrexate, no | 59 (12.5%) | 62 (16.3%) |
| Past non‐TNF inhibitor biologic DMARD use | 1 (0.2%) | 1 (0.3%) |
| Past TNF blocker use | 1 (0.2%) | 19 (5.0%) |
| Baseline use of oral corticosteroids | 221 (46.7%) | 200 (52.6%) |
| History of cancer (not nonmelanomatous skin cancer) | 7 (1.5%) | 9 (2.4%) |
| History of CVD (HF, CAD, PVD) | 38 (8.0%) | 26 (6.8%) |
| History of hypertension | 138 (29.2%) | 133 (35.0%) |
| History of COPD/asthma | 29 (6.1%) | 28 (7.4%) |
| History of hyperlipidemia | 76 (16.1%) | 76 (20.0%) |
| History of liver disease | 5 (1.1%) | 7 (1.8%) |
| History of renal disease | 2 (0.4%) | 3 (0.8%) |
| History of diabetes | 33 (7.0%) | 27 (7.1%) |
| Number of comorbidities | ||
| None | 253 (53.5%) | 192 (50.5%) |
| One | 145 (30.7%) | 105 (27.6%) |
| Two or more | 75 (15.9%) | 83 (21.8%) |
Abbreviation: BMI, body mass index; CAD, coronary artery disease; CDAI, Clinical Disease Activity Index; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; CVD, cardiovascular disease; DMARD, disease‐modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ‐DI, Health Assessment Questionnaire Disability Index; HF, heart failure; PVD, peripheral vascular disease; TNF, tumor necrosis factor.
a
n (%) is presented for categorical variables. The median (25th percentile, 75th percentile) is presented for continuous variables.